• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the Canadian Academy of Child and Adolescent Psychiatry >A Review of Escitalopram and Citalopram in Child and Adolescent Depression
【24h】

A Review of Escitalopram and Citalopram in Child and Adolescent Depression

机译：依西酞普兰和西酞普兰治疗儿童和青少年抑郁症的研究进展

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review the basic pharmacology and published literature regarding escitalopram and citalopram in child and adolescent depression. Methods: A literature review was conducted using the search terms: ‘escitalopram’, ‘citalopram’, ‘depression’, ‘randomized controlled trial’, ‘open label trial’ and limits set to: Human trials, English Language and All Child (Age 0–18). Additional articles were identified from reference information and poster presentation data. Results: Three prospective, randomized controlled trials (RCT) were found for escitalopram in pediatric depression, and two RCTs were found for citalopram. One RCT each for escitalopram and citalopram showed superiority over placebo on the primary out come measure. Adverse effects in escitalopram and citalopram trials were generally mild to moderate. Suicidality was not assessed systematically in all RCTs reviewed, but did not appear to be elevated over placebo in escitalopram RCTs. One trial reported numerically higher suicide related events for citalopram compared to placebo (14 vs. 5, p=0.06). Conclusion: At present, escitalopram and citalopram should be considered a second-line option for adolescent depression. The US Food and Drug Administration approval of escitalopram for treatment of adolescent depression was based on a single positive RCT. This is less evidence than typically required for approval of a drug for a new indication.
机译：目的：综述依西酞普兰和西酞普兰在儿童和青少年抑郁症中的基本药理作用和已发表的文献。方法：使用以下检索词进行文献综述：“依他普仑”，“依他普仑”，“抑郁症”，“随机对照试验”，“公开标签试验”，并设定以下范围：人体试验，英语和所有儿童（年龄0–18）。从参考信息和海报展示数据中识别出其他文章。结果：发现三项前瞻性，随机对照试验（RCT）用于小儿抑郁症中的依他普仑，而二项RCT则用于西酞普兰。依他普仑和西酞普兰各有一项RCT在初次服用时显示出优于安慰剂的优势。依他普仑和西酞普兰试验的不良反应一般为轻度至中度。在所有审查的RCT中并未对自杀倾向进行系统评估，但依他普仑RCT中的自杀倾向似乎并未高于安慰剂。一项试验报道西酞普兰的自杀相关事件在数字上高于安慰剂（14 vs. 5，p = 0.06）。结论：目前，依西酞普兰和西酞普兰应被视为青少年抑郁症的二线治疗方案。美国食品药品监督管理局批准艾司西酞普兰用于治疗青少年抑郁症是基于单个阳性RCT。这比批准新适应症药物通常所需的证据少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号